A novel treatment (MA-5) developed by a Tohoku University-led research team will soon undergo phase II clinical trials at ...

Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in a global Phase 3 trial for Stargardt ...

STOCKHOLM, SE / ACCESS Newswire / December 3, 2025 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a pharmaceutical ...

GRIN Therapeutics, Inc., a leader in the development of targeted disease-specific therapies to treat serious ...

Company plans to discuss results and regulatory pathway of IGV-001 with U.S. FDA in the coming months -- Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole ...

Kv7.2/7.3 is a voltage-gated potassium channel whose role is crucial for the regulation of both neuronal excitability and membrane potential. QurAlis is currently planning a Phase 2 clinical trial to ...

GTA182 demonstrates favorable safety, dose-proportional pharmacokinetics, robust PRMT5 pathway inhibition, and encouraging early antitumor ...

The drug was well tolerated throughout all doses, with two discontinuations due to adverse events.

The Phase II OCULE-01 study in uveal melanoma started in March 2025, the PULMO-01 study in non-small cell lung cancer (NSCLC) started in May 2025 and the HEMA-MED Phase I/II study in myelofibrosis ...

Under the partnership, Lilly will pay IU up to $40 million to build clinical trial infrastructure, accelerate access to ...

Researchers at the University of Colorado Cancer Center have discovered a novel therapy combination that could offer new hope ...

The donation will establish the Harold B. Smith Family Cancer Research Center at Rush within the Rush MD Anderson Cancer Center.